Table 2.
Comparison of demographic, clinical, and ECG characteristics by the ECG referral
| Non-cardiologist N=2,856 |
Unknown N=2,819 |
Cardiologist N=1,143 |
ANOVAP-value | |||||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Use of medication | Any time | currently | Any time | currently | Any time | currently | Any time | currently |
| Age (SD), y | 59.5(15.3) | 56.3(16.9) | 59.2(16.1) | <0.0001 | ||||
| Female, n(%) | 1,345(47.1) | 1,211(43.0) | 490(42.9) | 0.003 | ||||
| Ordered in Intensive Care Unit or ED, n(%) | 14(0.5) | 70(2.5) | 35(3.1) | <0.0001 | ||||
|
| ||||||||
| Coronary heart disease, n(%) | 382(13.4) | 378(13.4) | 224(19.6) | <0.0001 | ||||
| History of myocardial infarction, n(%) | 129(4.5) | 148(5.3) | 84(7.4) | 0.001 | ||||
| History of CABG, n(%) | 48(1.7) | 51(1.8) | 37(3.2) | 0.004 | ||||
| Heart failure, n(%) | 309(10.8) | 377(13.4) | 214(18.7) | <0.0001 | ||||
| New Implantable Cardioverter Defibrillator, n(%) | 76(2.7) | 77(2.7) | 70(6.1) | <0.0001 | ||||
| New Pacemaker, n(%) | 57(2.0) | 56(2.0) | 55(4.8) | <0.0001 | ||||
| Chronic obstructive pulmonary disease, n(%) | 147(5.2) | 186(6.6) | 64(5.6) | 0.062 | ||||
| Chronic liver disease, n(%) | 97(3.4) | 122(4.3) | 27(2.4) | 0.008 | ||||
| Diabetes mellitus, n(%) | 481(16.8) | 503(17.8) | 192(16.8) | 0.551 | ||||
| Chronic kidney disease, n(%) | 44(1.5) | 25(0.9) | 11(1.0) | 0.056 | ||||
|
| ||||||||
| Ever prescribed any medication at OHSU, n(%) | 2,642(92.5) | 2,462(87.3) | 1,070(93.6) | <0.0001 | ||||
| ACE inhibitors/ARBs, n(%) | 871(30.5) | 475(16.6) | 783(27.8) | 446(15.8) | 386(33.8) | 227(19.9) | 0.001 | 0.008 |
| Antiarrhythmic drugs, n(%) | 79(2.8) | 39(1.4) | 72(2.6) | 41(1.5) | 64(5.6) | 38(3.3) | <0.0001 | |
| Anticoagulants, n(%) | 346(12.1) | 204(7.1) | 302(10.7) | 174(6.2) | 183(16.0) | 111(9.7) | <0.0001 | |
| Anti-platelets/ASA, n(%) | 1,120(39.2) | 584(20.5) | 1,017(36.1) | 559(19.8) | 558(48.8) | 331(29.0) | <0.0001 | |
| Beta blockers, n(%) | 1,045(36.6) | 594(20.8) | 958(34.0) | 559(19.8) | 488(42.7) | 306(26.8) | <0.0001 | |
| Calcium channel blockers, n(%) | 481(16.8) | 249(8.7) | 424(15.0) | 228(8.1) | 172(15.1) | 92(8.1) | 0.133 | 0.639 |
| Diuretics, n(%) | 789(27.6) | 442(15.5) | 727(25.8) | 422(15.0) | 369(32.3) | 221(19.3) | <0.0001 | 0.002 |
| Nitrates/hydralazine, n(%) | 143(5.0) | 90(3.2) | 165(5.9) | 88(3.1) | 87(7.6) | 44(3.9) | 0.006 | 0.463 |
| Statins, n(%) | 988(34.6) | 509(17.8) | 879(31.2) | 484(17.2) | 482(42.2) | 285(24.9) | <0.0001 | |
|
| ||||||||
| P-prime V1 amplitude, μV(SD) | −118.6(19.2) | −120.0(19.6) | −120.3(20.5) | 0.092 | ||||
| Heart rate, bpm(SD) | 79.4(21.5) | 85.6(22.0) | 77.6(19.0) | <0.0001 | ||||
| PR interval, n(SD) | 146.3(53.6) | 146.6(48.8) | 149.7(57.8) | 0.171 | ||||
| QTc interval, n(SD) | 445.1(38.6) | 450.2(38.2) | 450.6(41.4) | <0.0001 | ||||